There were 1,413 press releases posted in the last 24 hours and 397,324 in the last 365 days.

The Oncology Institute Expands into Miami-Dade County, Hires National Oncology Leader Dr. Roberto Ochoa

TOI continues expansion in South Florida

CERRITOS, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based community oncology groups in the United States, announced its entrance into Miami-Dade County, Florida with the acquisition of Hematology/Oncology Associates of Miami and the addition of a Senior Medical Director for Florida, further strengthening their investment in South Florida.

Dr. Roberto Ochoa, former National Director, Hematology/Oncology and Palliative Care at ChenMed, will serve as the newly appointed Senior Medical Director for the state of Florida. Dr. Ochoa, who will also be seeing patients at the South Miami clinic, shared, “I am enthusiastic to begin working for the leader in value-based oncology as it expands throughout the region. I have been paying close attention to TOI for quite some time and I am looking forward to working with the team to serve our existing patients and welcome new patients all while providing excellent care.”

Dr. Pedro De La Rosa Costa, former principal of Hematology/Oncology Associates of Miami now the TOI South Miami clinic, shared, “I am very excited about this partnership because TOI prioritizes patients just as much as I do. Their value-based model is a perfect fit to my practice, and I know my patients will benefit from this new relationship.”

“Dr. Ochoa’s leadership will play a critical role in bringing TOI’s high-quality, value-based model of care to more communities throughout the state of Florida,” shared TOI’s Chief Executive Officer, Brad Hively. “We are happy to welcome him and Dr. De La Rosa Costa as we enter the Miami-Dade market. This is just the beginning of our investment in the region and we look forward to adding new locations and physicians in the coming year.”

The South Miami Clinic (Formerly Hematology/Oncology Associates of Miami) located at 9350 SW 72nd St, Miami, FL 33173, will continue to serve patients without interruption. An expanded, renovated office is under construction at 6262 Sunset Drive, STE 303 South Miami, FL 33143 and is expected to open before the end of the year. Additional clinic locations in Dade County are expected to open in 2023.

About TOI
Founded in 2007, TOI is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.7 million patients including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With 90+ employed clinicians and more than 700 teammates in over 50 clinic locations and growing, TOI is changing oncology for the better. For more information visit

Forward-Looking Statements
This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements are based on various assumptions and on the current expectations of The Oncology Institute and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of The Oncology Institute. These forward-looking statements are subject to a number of risks and uncertainties, including the outcome of judicial and administrative proceedings to which The Oncology Institute may become a party or governmental investigations to which The Oncology Institute may become subject that could interrupt or limit The Oncology Institute’s operations, result in adverse judgments, settlements or fines and create negative publicity; changes in The Oncology Institute’s clients’ preferences, prospects and the competitive conditions prevailing in the healthcare sector; the risk that any required regulatory approvals could adversely affect the company; failure to continue to meet stock exchange listing standards; the impact of COVID-19 on the company’s business; those factors discussed in the documents of TOI filed, or to be filed, with the SEC. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that The Oncology Institute presently does not know or that The Oncology Institute currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect The Oncology Institute’s expectations, plans or forecasts of future events and views as of the date of this press release. The Oncology Institute anticipates that subsequent events and developments will cause The Oncology Institute’s assessments to change. The Oncology Institute does not undertake any obligation to update any of these forward-looking statements. These forward-looking statements should not be relied upon as representing The Oncology Institute’s assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.


The Oncology Institute
Julie Korinke
(562) 735-3226 x 88806

Solebury Trout
Maria Lycouris

Primary Logo